Quantcast

Latest The New England Journal Stories

2013-01-17 13:30:25

Earlier therapy enhances restoration of CD4+ T-cell counts Patients who are started on antiretroviral therapy for HIV-1 infection within four months of estimated infection date – and who have higher counts of CD4+ T-cells at the initiation of therapy – demonstrate a stronger recovery of CD4+ T-cell counts than patients in whom therapy is started later, a new study shows. The report, to be published Thursday in The New England Journal of Medicine, is co-authored by physicians...

2012-07-05 10:17:04

Preventing postoperative delirium may improve recovery of cognitive ability in cardiac patients Older patients undergoing cardiac surgery often experience changes in cognitive function, such as memory problems or an inability to focus, in the days immediately following their operations. While these changes are usually temporary, for unknown reasons, a significant number of cardiac patients will encounter long-term cognitive problems, lasting as long as a year after their surgeries. Now,...

2012-06-21 15:35:59

A multicenter study involving a UT Southwestern Medical Center urogynecologist will eliminate some of the guesswork physicians face about whether to use a sling during vaginal prolapse repair to prevent urinary incontinence. The clinical investigation from eight medical centers across the U.S. provides the first surgical outcome evidence on the benefits and risks of midurethral slings for women with vaginal prolapse who show no symptoms of urinary incontinence before surgery. One in...

FDA Report Suggests Women Reassess Bone Drug Use Due To Serious Adverse Events
2012-05-11 12:45:33

A new analysis of popular bone-building drugs by the US Food and Drug Administration (FDA) could prompt millions of women to rethink their use of such drugs, even though the agency fell short of issuing specific recommendations. The FDA said doctors need to reassess which women are likely to benefit from bisphosphonates such as Fosamax, Actonel and Reclast, given the lack of concrete evidence that taking them over long periods really helps them and the possibility that they can put some...

2012-03-15 12:40:58

A new topical gel now available by prescription significantly decreases the amount of time needed to treat actinic keratosis, a skin condition that is a common precursor to skin cancer, according to a multi-center trial led by researchers at Mount Sinai School of Medicine. The gel, called ingenol mebutate, is applied to the skin for just a few days, making it quicker and even more effective as current therapies require weeks to months to apply. The Phase III study results of the trial are...

2012-02-09 12:24:04

The cost of medications through Medicare's subsidized prescription drug program varies from region to region across the United States largely due to the use of more expensive brand-name drugs and not because of the amount of drugs prescribed, according to a study led by researchers from the University of Pittsburgh Graduate School of Public Health (GSPH). The authors said that more efficient prescribing practices could have saved the Medicare program and its beneficiaries $4.5 billion. The...

2011-12-08 13:33:48

Norovirus VLP vaccine is first ever to demonstrate significant protection against acute norovirus gastroenteritis in Phase I/II study LigoCyte Pharmaceuticals, Inc. announced today that its experimental vaccine provided significant protection against norovirus infection and related gastrointestinal illness collectively known as acute gastroenteritis (AGE). Norovirus infection, sometimes referred to as "the stomach flu" is one of the most common causes of severe nausea, vomiting, abdominal...

2011-11-10 18:30:46

Offers Guidance on Risk Factors, Possible Causes and Interventions to Help Prevent Sudden, Unexpected Death in Epilepsy Over time, epileptic seizures can lead to major health issues, including significant cognitive decline and even death, warns Orrin Devinsky, MD, professor, Departments of Neurology, Neurosurgeryand Psychiatryat NYU Langone Medical Center.  In a review article in the November 10, 2011 issue of the New England Journal of Medicine, Devinsky addresses the magnitude of...

2011-10-06 10:58:34

The drug also increased the length of time before a patient relapsed and more patients taking it remained free of relapses A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease. The results of the Phase 3 trial of the drug teriflunomide were published in The New England Journal of Medicine on Thursday. "This could be a safe, effective and convenient...

2011-09-15 11:34:05

A new multinational study finds that a 24-week treatment course for hepatitis C that adds telaprevir to peginterferon alfa and ribavirin is just as effective as a 48-week regimen for many patients. This is good news for up to 4 million people in the U.S. who suffer from this chronic liver disease, many of whom will undergo treatment for hepatitis C, said Michael W. Fried, MD, professor of medicine at the University of North Carolina at Chapel Hill, director of the UNC Liver Center and a...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related